Horama

Please note: The information displayed on this page might be outdated.
Horama: HORAMA develops new gene therapies for rare inherited ocular diseases and CNS diseases . HORAMA’s approach is based on vector technology using non-pathogenic, recombinant adeno-associated viruses (rAAV) and new generation of modified rAAV (mrAAV). The company's lead candidate is HORA-PDE6B, which is in Phase I/II clinical trials with an indication in PDE6B retinitis pigmentosa.

The company raised EUR 22.5 million of Series B venture funding from Kurma Partners, Pontifax Venture Capital, Fund+ on November 8, 2017. V-Bio, Turenne Capital, IdInvest Partners, GO Capital, Sham Innovation Santé and Omnes Capital also participated in the round.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Ophthalmology, Rare Disease
Industry
Biotechnology
Listing
Private
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy, Gene Therapy
Website:
Profiles:
Address:
27 rue du Faubourg Saint-Jacques
Paris, Ile-de-France 75014
France

Company Participants at European Biotech Investor Days 2021

Rodolphe Clerval
Horama, Chief Business Officer
Rodolphe Clerval has over 18 years’ international experience in the pharma and biotech industry. Prior to joining HORAMA, Mr. Clerval was co-founder and Chief Business Officer at Enterome. During his tenure at Enterome, he has executed over 15 transactions, including major industrial partnerships with Takeda, J&J, BMS, Abbvie and Nestle Health Sciences. Rodolphe previously worked with TcLand Expression and Genzyme in business development, and with Natixis as sell-side equity analyst. He started his career at Aventis Animal Nutrition as a scientist. Rodolphe holds a degree in Biochemical Engineering from Polytech Marseille.